new technologies informing soc in dlbcl
Published 6 years ago • 61 plays • Length 3:02Download video MP4
Download video MP3
Similar videos
-
2:21
the role of molecular subtyping in dlbcl and implications for treatment decisions
-
4:01
first- and second-line treatment in dlbcl
-
0:58
improving second-line treatments in dlbcl
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:12
exciting advances in dlbcl: molecular characterization of subtypes & novel immunotherapeutic agents
-
2:03
current soc for bpdcn and other emerging treatment options
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:53
autohct in dlbcl in the car-t era
-
1:15
personalized medicine for dlbcl
-
7:16
changes in the classification of dlbcl
-
2:03
the next generation of novel agents in development for aggressive b-cell lymphoma
-
0:59
hdxsim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in scd
-
1:46
towards a personalized treatment approach for scd
-
3:04
applying molecular understanding of dlbcl to management strategies
-
2:21
practical considerations for dli after haploidentical sct
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml